## Stroke in Women Recognizing Opportunities for Prevention Shirin Jalini, MD, FRCPC









## Disclosures

### Relationships with commercial interests: None Potential for conflict(s) of interest: None

## Objectives

1) Review the stroke risk factors that are unique to women

1) Review the impact of conventional stroke risk factors on women

## Stroke Risk Factors Unique to Women

Pregnancy Endogenous Hormones Exogenous Hormones



Pregnancy



- Affects ≈30 women for every 100,000 pregnancies
- Preeclampsia confers a 40-fold increase in risk of true ischemic stroke- single most important risk factor for both ischemic and ICH.
  - 24-48% of strokes in pregnancy are associated with eclampsia and preeclampsia.<sup>1</sup>
- Hallmarks of prevention:
  - Frequent antenatl blood pressure measurements
  - Screening for signs and symptoms of toxemia in the latter half of pregnancy

## **Pregnancy: Preeclampsia**



Control of Hypertension in Pregnancy (CHiPS Trial)<sup>1</sup>

- Safe to tightly control BP
- Supports use of aggressive utilization of antihypertensives for prevention of malignant hypertension









#### **Prevention of Preeclampsia in high risk patients**

- ASA <sup>2</sup>
- Repletion of low calcium <sup>3</sup>

1 NEJM 2015: 372: 407-417 2 NEJM 2017; 377:613-622 3 Cochrane Database 2014: 6:CD001059

## **Long-Term Ramifications**

- BP often normalizes after delivery
- But vascular risk does not return to baseline
  - Although it remains unclear if preeclampsia serves as a marker for future stroke or is within the causal pathway of arterial dysfunction, an 80% increased risk of stroke among those with history of preeclampisa persists later in life
- It may be decades before these women have formal cardiovascular risk factor screening and treatment, thereby accumulating atherosclerotic burden all the while.

## Peripartum & Post Partum



- Stroke risk (both ischemic and ICH) is highest in the peripartum period remains high up to 6 weeks postpartum.
  - Normal stroke risk in women of child bearing age: 25/100,000<sup>1</sup>
  - Increases 9-fold in peripartum period
  - Increases 3-fold in the postpartum period
- Risk of ANY thrombotic event remains high up to 12 weeks postpartum

## **Pregnancy in Women with Prior Stroke**

 Limited data from case series suggests an absolute risk of recurrent arterial ischemic stroke associated with pregnancy 0.7% (95%CI 0.04-4.4%)- area for future study. <sup>1-3</sup>

 Risk most likely depends on specific clinical circumstance

## **Pregnancy in Women with Prior Stroke**

• strokebestpractices.ca

Canadian stroke best practice consensus statement: Secondary stroke prevention during pregnancy International Journal of Stroke 2018, Vol. 13(4) 406-419 © 2017 World Stroke Organization Reprints and permissions: sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/1747493017743801 journals.sagepub.com/home/wso



### **Endogenous Hormones:** Estrogen, Testosterone, DHEAS

 Data on relationship between endogenous hormones and risk of stroke is limited



- Estradiol
  - Meta-analysis of available studies have shown no relationship between estradiol levels and risk if ischemic stroke.<sup>1</sup>
- Testosterone
  - Although low testosterone has been associated with increased risk of stroke in men, no clear relationship has been shown to exist between testosterone and risk of stroke.<sup>2</sup>
- Dehydroepiandrosterone (DHEAS)
  - Endogenous adrenal hormone used for synthesis of estrogen and testosterone
  - Inversely related to both stroke incidence and severity <sup>4-5</sup>

1 J Clin Endocrinol Metab 2016:101:69-783 Metabolism 2012; 61:84-912 JAHA 2012; 1:e0013884 J Clin Endocrinol Metab 2010; 95:4985-4992

### **Endogenous Hormones:** Age at Natural and Surgical Menopause



- Women of reproductive age are at a lower risk of CVD compared to men of similar age and lifestyle.
- But women who experience early menopause have increase cardiovascular risk<sup>1</sup>
- Nurses Health Study
  - bilateral oopherectomy before age 50 associated with increased risk of CVD mortality in women, especially if no hormone therapy is used.<sup>2</sup>
- Therefore, CVD incidence rising sharply after menopause suggests protective benefits of ovarian hormones.
- Reasons unclear. Perhaps due to increased rates of atherosclerosis due increase LDL and decreased HDL.

### **Exogenous Hormones:** Hormone-Containing Birth Control



- Combined oral contraceptives are thrombogenic
- Second and third generation COCs continue to have a 60-80% increased risk of MI/Stroke in users compared to non-users.<sup>1</sup>
- Progestogen-only hormonal contraceptives have not been associated with increased risk of stroke (data is limited).<sup>2</sup>
- Nonoral methods of delivery of combined hormonal contraceptives including vaginal rings and patches seem to have the same risk as their oral counterparts <sup>3</sup>

### Exogenous Hormones: Hormone-Containing Birth Control and Migraine



- People with migraine are at increased risk of ischemic stroke.
  - Increased risk is ≈ 2-fold and only apparent in those who have migraine with aura (not in those without aura). <sup>1</sup>
  - Also ≈ 2-fold increased risk in women compared to men
- Women with migraine with aura + COCs have further increased risk (7.02 [95% CI, 1.51-32.68])
- Women with migraine with aura + COC + smoking have even higher risk (RR 10 [95% CI, 1.4-73.7]
- Women with migraine with aura should be adviced to control all modifiable risk factors and birth methods other than COCs should be considered.

#### **Exogenous Hormones:** Postmenopausal Hormone Therapy

– Women's Health Initiative <sup>1-2</sup>



- RCT- women aged 50-79. Combined estrogen + progestrone vs estrogen alone vs placebo
- Postmenopausal hormone therapy increased stroke risk
  - 31% [Cl 2%-68%] estrogen + progesterone
  - 37% [CI 9-73%] estrogen alone
- Although subgroup analyses highlighted that stroke risk varies depending on woman's age, HRT is not recommended for stroke and other chronic disease prevention

#### **Exogenous Hormones:** Transgender Medicine



- Transwomen: assigned male, identify as female
  - Undergo treatment with estrogen, antiandrogens
  - Antiandrogens: usually spironlactone- does not seem to increase thrombotic risk
  - Estrogen: direct evidence of transwomen is scant. Most comes from small case control studies
  - <u>Current Recommendation</u>: Maintain a high index of suspicion for deep venous thrombosis/ PE/ CVST in transwomen on estrogen. Care provider should strongly encourage smoking cessation and maintain a close eye on cardiovascular risk profile. <sup>1</sup>

1 Stroke 2018; 49 (3) 518-523

#### **Exogenous Hormones:** Transgender Medicine



- Transmen: assigned female, identify as male
  - Undergo treatment with testosterone
  - Testosterone does now seem to be associated with increased risk of thromboembolic complication
  - Majority of studies of transmen do not suggest an increased risk of cardiovascular morbidity with exogenous testosterone therapy. <sup>1-3</sup>

| Exposure                                   | Risk<br>Association | Further Research<br>Needed |  |  |
|--|---------------------|----------------------------|--|--|
| Endogenous hormones                        |                     |                            |  |  |
| Early age at menarche (<10 y)              | 1                   |                            |  |  |
| Early age at menopause/BSO (<45 y)         | 1                   |                            |  |  |
| Reproductive lifespan                      | ?                   | Yes                        |  |  |
| Low DHEAS                                  | 1                   |                            |  |  |
| Estradiol                                  | ?                   | Yes                        |  |  |
| Testosterone                               | $\rightarrow$       |                            |  |  |
| Exogenous hormones                         |                     |                            |  |  |
| PMH: oral estrogens                        | 1                   |                            |  |  |
| PMH: transdermal estrogens                 | ?                   | Yes                        |  |  |
| Combined oral contraceptives               | 1                   |                            |  |  |
| Progestogen-only contraceptives            | $\rightarrow$       | Yes                        |  |  |
| Transgender exogenous estrogens            | 1                   | Yes                        |  |  |
| Transgender exogenous testosterones        | $\rightarrow$       | Yes                        |  |  |
| Pregnancy-related exposures                |                     |                            |  |  |
| Pregnancy/peripartuition                   | <b>↑</b>            |                            |  |  |
| Gestational diabetes mellitus              | ↑                   |                            |  |  |
| Hypertension in pregnancy/<br>preeclampsia | Ť                   | Yes                        |  |  |

Stroke 2018: 49: 518-523

# Impact of Conventional Stroke Risk Factors on Women

Hypertension Dyslipidemia Atrial Fibrillation Diabetes Mellitus

| Risk Factor          | Prevalence  | Association With IS   | Treatment Disparity  |
|----------------------|---|---|--|
| Hypertension         | Lower in women (vs men) in younger<br>age groups, higher in older age<br>groups | Similar in women (vs men) in<br>younger age groups, higher in older<br>age groups | In younger age groups, women more likely<br>to have BP controlled; in older age groups,<br>women less likely to have BP controlled   |
| Dyslipidemia         | Data conflict; either similar between sexes or lower in women                   | Lower in women  | Women less likely to be on statins and have LDL controlled   |
| Atrial fibrillation  | Higher in women   | Higher in women   | Women less likely to be prescribed oral<br>anticoagulants, less likely to have cardiac<br>ablation, and receive lower doses of NOACs |
| Migraine             | Higher in women   | Higher in women   | Unknown if migraine treatment reduces<br>stroke risk   |
| Diabetes mellitus    | Similar women vs men  | Higher in women   | Data conflict on sex differences in meeting<br>HbA1c goal  |
| Cognitive impairment | Higher in women   | Unknown whether there is a sex difference   | Women less likely to be treated with<br>antidementia drugs   |

| Risk Factor          | Prevalence  | Association With IS   | Treatment Disparity  |
|----------------------|---|---|--|
| Hypertension         | Lower in women (vs men) in younger<br>age groups, higher in older age<br>groups | Similar in women (vs men) in<br>younger age groups, higher in older<br>age groups | In younger age groups, women more likely<br>to have BP controlled; in older age groups,<br>women less likely to have BP controlled   |
| Dyslipidemia         | Data conflict; either similar between<br>sexes or lower in women                | Lower in women  | Women less likely to be on statins and have LDL controlled   |
| Atrial fibrillation  | Higher in women   | Higher in women   | Women less likely to be prescribed oral<br>anticoagulants, less likely to have cardiac<br>ablation, and receive lower doses of NOACs |
| Migraine             | Higher in women   | Higher in women   | Unknown if migraine treatment reduces<br>stroke risk   |
| Diabetes mellitus    | Similar women vs men  | Higher in women   | Data conflict on sex differences in meeting<br>HbA1c goal  |
| Cognitive impairment | Higher in women   | Unknown whether there is a sex difference   | Women less likely to be treated with<br>antidementia drugs   |

| Risk Factor          | Prevalence  | Association With IS   | Treatment Disparity  |
|----------------------|---|---|--|
| Hypertension         | Lower in women (vs men) in younger<br>age groups, higher in older age<br>groups | Similar in women (vs men) in<br>younger age groups, higher in older<br>age groups | In younger age groups, women more likely<br>to have BP controlled; in older age groups,<br>women less likely to have BP controlled   |
| Dyslipidemia         | Data conflict; either similar between sexes or lower in women                   | Lower in women  | Women less likely to be on statins and have LDL controlled   |
| Atrial fibrillation  | Higher in women   | Higher in women   | Women less likely to be prescribed oral<br>anticoagulants, less likely to have cardiac<br>ablation, and receive lower doses of NOACs |
| Migraine             | Higher in women   | Higher in women   | Unknown if migraine treatment reduces<br>stroke risk   |
| Diabetes mellitus    | Similar women vs men  | Higher in women   | Data conflict on sex differences in meeting<br>HbA1c goal  |
| Cognitive impairment | Higher in women   | Unknown whether there is a sex difference   | Women less likely to be treated with<br>antidementia drugs   |

| Risk Factor          | Prevalence  | Association With IS   | Treatment Disparity  |
|----------------------|---|---|--|
| Hypertension         | Lower in women (vs men) in younger<br>age groups, higher in older age<br>groups | Similar in women (vs men) in<br>younger age groups, higher in older<br>age groups | In younger age groups, women more likely<br>to have BP controlled; in older age groups,<br>women less likely to have BP controlled   |
| Dyslipidemia         | Data conflict; either similar between sexes or lower in women                   | Lower in women  | Women less likely to be on statins and have LDL controlled   |
| Atrial fibrillation  | Higher in women   | Higher in women   | Women less likely to be prescribed oral<br>anticoagulants, less likely to have cardiac<br>ablation, and receive lower doses of NOACs |
| Migraine             | Higher in women   | Higher in women   | Unknown if migraine treatment reduces<br>stroke risk   |
| Diabetes mellitus    | Similar women vs men  | Higher in women   | Data conflict on sex differences in meeting<br>HbA1c goal  |
| Cognitive impairment | Higher in women   | Unknown whether there is a sex difference   | Women less likely to be treated with<br>antidementia drugs   |

| Risk Factor          | Prevalence  | Association With IS   | Treatment Disparity  |
|----------------------|---|---|--|
| Hypertension         | Lower in women (vs men) in younger<br>age groups, higher in older age<br>groups | Similar in women (vs men) in<br>younger age groups, higher in older<br>age groups | In younger age groups, women more likely<br>to have BP controlled; in older age groups,<br>women less likely to have BP controlled   |
| Dyslipidemia         | Data conflict; either similar between sexes or lower in women                   | Lower in women  | Women less likely to be on statins and have LDL controlled   |
| Atrial fibrillation  | Higher in women   | Higher in women   | Women less likely to be prescribed oral<br>anticoagulants, less likely to have cardiac<br>ablation, and receive lower doses of NOACs |
| Migraine             | Higher in women   | Higher in women   | Unknown if migraine treatment reduces<br>stroke risk   |
| Diabetes mellitus    | Similar women vs men  | Higher in women   | Data conflict on sex differences in meeting<br>HbA1c goal  |
| Cognitive impairment | Higher in women   | Unknown whether there is a sex difference   | Women less likely to be treated with<br>antidementia drugs   |

| Risk Factor          | Prevalence  | Association With IS   | Treatment Disparity  |
|----------------------|---|---|--|
| Hypertension         | Lower in women (vs men) in younger<br>age groups, higher in older age<br>groups | Similar in women (vs men) in<br>younger age groups, higher in older<br>age groups | In younger age groups, women more likely<br>to have BP controlled; in older age groups,<br>women less likely to have BP controlled   |
| Dyslipidemia         | Data conflict; either similar between sexes or lower in women                   | Lower in women  | Women less likely to be on statins and have LDL controlled   |
| Atrial fibrillation  | Higher in women   | Higher in women   | Women less likely to be prescribed oral<br>anticoagulants, less likely to have cardiac<br>ablation, and receive lower doses of NOACs |
| Migraine             | Higher in women   | Higher in women   | Unknown if migraine treatment reduces<br>stroke risk   |
| Diabetes mellitus    | Similar women vs men  | Higher in women   | Data conflict on sex differences in meeting<br>HbA1c goal  |
| Cognitive impairment | Higner in women   | Unknown wnether there is a sex<br>difference                                      | women less likely to be treated with<br>antidementia drugs   |

### **Conventional Stroke Risk Factors and Women**

- These potentially modifiable risk factors account for 90% of the population attributable risk for stroke.
- Failure of stroke prevention in women most commonly occurs because women are systemically underscreened and undertreated in modifying these widely recognizable risk factors.
- Therefore it is in risk factor screening and treatment intensification where clinicians can best ameliorate the gender caps in stroke outcomes and prevention

## Take away points

- Sex-specific risk factors exists at all ages and stages of life.
- Mediated by unique physiological stress of pregnancy, endogenous or exogenous hormones or traditional risk factors.
- Emphasis on aggressive treatment of obesity, hypertension, dyslipidemia, diabetes, smoking and AF in women

• Thank you!